Alibaba to inject online pharmacy business into listed healthcare unit
Category: #health  By Paroma Bhattacharya  Date: 2018-05-30
  • share
  • Twitter
  • Facebook
  • LinkedIn

Alibaba to inject online pharmacy business into listed healthcare unit

Alibaba Group Holding Ltd, the Chinese e-commerce giant will be injecting some of its online pharmacy business to Alibaba Health Information Technology for HK$10.6 billion ($1.35 billion). Alibaba Group will be selling Ali JK Nutritional Products Holding Ltd, a part of the Alibaba Tmall platform. Ali JK Nutritional Products controls the sale of healthcare products, medical devices, healthcare services and adult products.

Through the deal Alibaba will receive shares in Ali Health which will increase Alibaba’s economic interest in the form from 48.1% to 56.2%. The deal will also give Alibaba a voting interest of 67.5% in Ali Health. The deal will bolster Ali Health’s position in the rapidly growing healthcare technology market of China. Companies like WeDoctor, a Tencent backed platform and Ping An Healthcare have created a competitive scenario in the healthcare industry in China where Ali Health have to vie to hold their prominent positions.

Daniel Zhang, CEO, Alibaba, reportedly expressed his ambition of turning Ali Health into China’s best healthcare ecosystem with the reinforcement the organization will receive through the deal. He added that healthcare is a strategically important field for Ali Health and the deal would help the firm capture the sphere. He also added that the deal would help the firm to expand its businesses and offer new health categories to patients.

According to a notable consultancy, the China healthcare industry spending should surpass $1 trillion by 2020 which is a significant increase from the 2011 estimates $357 billion. The growth will be augmented by technology firms looking to make inroads into the growing private healthcare market.

Ali Health said that the business unit, namely, Ali JK Nutritional Products Holding Limited, that is being injected into Ali Health had generated a gross merchandise volume of around ¥20.56 billion ($3.21 billion) in the financial year to March 31st with over 3,300 related merchants.

The deal is subject to approval from Ali Health shareholders and the Hong Kong stock exchange.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Outlook Therapeutics finishes patient registration for NORSE 1 trial
Outlook Therapeutics finishes patient registration for NORSE 1 trial
By Paroma Bhattacharya

  • NORSE 1 has registered a sum of 61 patients from nine different sites in Australia.
     
  • This study is first of the two current, well cont...

Lidl orders suppliers to pay duties on goods crossing Brexit borders
Lidl orders suppliers to pay duties on goods crossing Brexit borders
By Paroma Bhattacharya

  • The company has asked the British suppliers to pay any import tariffs levied on goods crossing borders after Brexit.
  • The current company contract c...

Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
Bio-Thera Solutions commences Phase 1 study for Simponi® biosimilar
By Paroma Bhattacharya

Bio-Thera Solutions, a China based pharmaceutical company, has reportedly announced the start of dosing of its first batch of healthy volunteers in order to compare the safety and pharmacokinetics of BAT2506, proposed ...